<?xml version='1.0' encoding='utf-8'?>
<document id="20608754"><sentence text="Drug-drug interaction profiles of proton pump inhibitors." /><sentence text="Proton pump inhibitors (PPIs) are widely prescribed for the treatment of gastric acid-related disorders and the eradication of Helicobacter pylori" /><sentence text=" In addition, they are routinely prescribed for the prevention of gastrointestinal bleeding in patients receiving a dual antiplatelet therapy consisting of clopidogrel and aspirin (acetylsalicylic acid) after myocardial infarction or percutaneous coronary intervention and stenting"><entity charOffset="156-167" id="DDI-PubMed.20608754.s3.e0" text="clopidogrel" /><entity charOffset="172-179" id="DDI-PubMed.20608754.s3.e1" text="aspirin" /><entity charOffset="181-201" id="DDI-PubMed.20608754.s3.e2" text="acetylsalicylic acid" /><pair ddi="false" e1="DDI-PubMed.20608754.s3.e0" e2="DDI-PubMed.20608754.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20608754.s3.e0" e2="DDI-PubMed.20608754.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20608754.s3.e0" e2="DDI-PubMed.20608754.s3.e2" /><pair ddi="false" e1="DDI-PubMed.20608754.s3.e1" e2="DDI-PubMed.20608754.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20608754.s3.e1" e2="DDI-PubMed.20608754.s3.e2" /></sentence><sentence text=" Because PPIs are given to these patients for long periods, there is a concern about the potential for clinically significant drug-drug interactions (DDIs) with concomitantly administered medications" /><sentence text=" Because PPIs give rise to profound and long-lasting elevation of intragastric pH, it is not surprising that they interfere with the absorption of concurrent medications" /><sentence text=" Drug solubility may be substantially reduced at neutral pH compared with acidic conditions" /><sentence text=" In this context, PPIs have been shown to reduce the bioavailability of many clinically relevant drugs (e" /><sentence text="g" /><sentence text=" ketoconazole, atazanavir) by 50% or more compared with the control values"><entity charOffset="1-13" id="DDI-PubMed.20608754.s9.e0" text="ketoconazole" /><entity charOffset="15-25" id="DDI-PubMed.20608754.s9.e1" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.20608754.s9.e0" e2="DDI-PubMed.20608754.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20608754.s9.e0" e2="DDI-PubMed.20608754.s9.e1" /></sentence><sentence text=" Soon after the introduction of omeprazole (a prototype PPI) into the market, it was reported that omeprazole was associated with 30% and 10% reductions in systemic clearance of diazepam and phenytoin, respectively"><entity charOffset="32-42" id="DDI-PubMed.20608754.s10.e0" text="omeprazole" /><entity charOffset="99-109" id="DDI-PubMed.20608754.s10.e1" text="omeprazole" /><entity charOffset="178-186" id="DDI-PubMed.20608754.s10.e2" text="diazepam" /><entity charOffset="191-200" id="DDI-PubMed.20608754.s10.e3" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e0" e2="DDI-PubMed.20608754.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e0" e2="DDI-PubMed.20608754.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e0" e2="DDI-PubMed.20608754.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e0" e2="DDI-PubMed.20608754.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e1" e2="DDI-PubMed.20608754.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e1" e2="DDI-PubMed.20608754.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e1" e2="DDI-PubMed.20608754.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e2" e2="DDI-PubMed.20608754.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20608754.s10.e2" e2="DDI-PubMed.20608754.s10.e3" /></sentence><sentence text=" In vitro studies demonstrating the inhibitory effects of omeprazole on the metabolism of these drugs with human liver microsomes gave a mechanistic explanation for the DDIs"><entity charOffset="58-68" id="DDI-PubMed.20608754.s11.e0" text="omeprazole" /></sentence><sentence text=" Numerous subsequent studies have been performed to investigate the DDI potential of PPIs associated with the metabolic inhibition of cytochrome P450 (CYP) enzyme activities; however, most such attempts have failed to find clinically relevant results" /><sentence text=" Nevertheless, recent large-scale clinical trials have raised concerns about possible DDIs between PPIs and an antiplatelet drug, clopidogrel"><entity charOffset="130-141" id="DDI-PubMed.20608754.s13.e0" text="clopidogrel" /></sentence><sentence text=" It has been suggested that coadministration of PPIs with a dual antiplatelet therapy consisting of clopidogrel and aspirin may attenuate the anti-aggregation effects of those medications and augment the risk of cardiovascular ischaemic events"><entity charOffset="100-111" id="DDI-PubMed.20608754.s14.e0" text="clopidogrel" /><entity charOffset="116-123" id="DDI-PubMed.20608754.s14.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.20608754.s14.e0" e2="DDI-PubMed.20608754.s14.e0" /><pair ddi="false" e1="DDI-PubMed.20608754.s14.e0" e2="DDI-PubMed.20608754.s14.e1" /></sentence><sentence text=" There is a possibility that PPIs may elicit detrimental effects by inhibiting CYP2C19-dominated metabolism of clopidogrel to its active metabolite"><entity charOffset="111-122" id="DDI-PubMed.20608754.s15.e0" text="clopidogrel" /></sentence><sentence text=" Further studies are urgently required to clarify the mechanism of this DDI and to explore new aspects of the DDI potential of PPIs" /><sentence text="" /></document>